The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers

Abstract EN

The present study aimed to determine the pharmacokinetic parameters and bioavailability of silymarin 140 mg SMEDDS formulation.

An open-label, single-dose pharmacokinetic study was conducted.

Twelve healthy volunteers were included in the study.

After the volunteers had fasted overnight for 10 h, a single-dose generic silymarin 140 mg SMEDDS soft capsule was administered.

Then 10 ml blood samples were taken at 0.0, 0.25, 0.50, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 h.

The plasma silybin concentrations were analyzed using validated LC-MS/MS.

The pharmacokinetic parameters were analyzed and calculated.

The pharmacokinetic parameters were calculated after silymarin had been administered as a single capsule.

The mean (range) Cmax was 812.43 (259.47–1505.47) ng/ml at 0.80 (0.25–1.67) h (tmax).

The mean (range) AUC0-t and AUC0-inf were 658.80 (268.29–1045.01) ng.h/ml and 676.98 (274.10–1050.96) ng.h/ml, respectively.

The mean ke and t1/2 were 0.5386 h-1 and 1.91 h, respectively.

The silymarin SMEDDS formulation soft capsule showed rapid absorption and high oral bioavailability.